Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HanchorBioTPE:7827 -0.32%9 PB Ratio is 47.39 as of Aug. 10, 2026, which is 79% above its 10-year median of 26.46. GuruFocus rates TPE:7827 with a GF Score™ of 9/100. Among 1,223 Biotechnology companies, HanchorBio ranks worse than 97.3% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-10), HanchorBio's share price is NT$156.00. HanchorBio's Book Value per Share for the quarter that ended in Mar. 2026 was NT$3.29. Hence, HanchorBio's PB Ratio of today is 47.39.
The historical rank and industry rank for HanchorBio's PB Ratio or its related term are showing as below:
TPE:7827'
s PB Ratio Range Over the Past 10 Years
Min: 11.65 Med: 26.46 Max: 56.2
Current: 47.39
During the past 4 years, HanchorBio's highest PB Ratio was 56.20. The lowest was 11.65. And the median was 26.46.
TPE:7827's PB Ratio is ranked worse than 97.3% of 1223
companies
in the Biotechnology industry
Industry Median: 2.94
vs TPE:7827: 47.39
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
HanchorBio PB Ratio Related Terms
HanchorBio PB Ratio Historical Data
* Premium members only.
The historical data trend for HanchorBio's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, HanchorBio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HanchorBio PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HanchorBio's PB Ratio distribution charts can be found below:
* The bar in red indicates where HanchorBio's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
HanchorBio's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
HanchorBio (TPE:7827) has a PB Ratio of 47.39 as of Aug. 10, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on HanchorBio and its competitors. This is 79% above median its historical median of 26.46. Over the past decade, HanchorBio's PB Ratio has ranged from 11.65 to 56.20. According to the industry distribution chart, HanchorBio ranks #1190 out of 1223 companies in the Biotechnology industry, placing it in the top 97.3%.
Is HanchorBio's PB Ratio too high?
HanchorBio's current PB Ratio of 47.39 is 79% above median its 10-year median of 26.46. Over the past 10 years, this metric has ranged from a low of 11.65 to a high of 56.20. The Biotechnology industry median PB Ratio is 2.94. HanchorBio's value of 47.39 is 1511.9% above this industry median. Based on the distribution chart, HanchorBio ranks #1190 out of 1223 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, HanchorBio has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does HanchorBio's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HanchorBio ranks #1190 out of 1223 companies for PB Ratio. This places HanchorBio in the lower half of its industry. The industry median PB Ratio is 2.94. HanchorBio's value of 47.39 is 1511.9% above this benchmark. Historically, HanchorBio's own PB Ratio has ranged from 11.65 to 56.20 over the past decade. While the company's 10-year median is 26.46 vs. the industry median of 2.94, HanchorBio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.94, based on 1,223 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HanchorBio's current PB Ratio of 47.39 is 1511.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on HanchorBio and its competitors. For the Biotechnology industry, the median PB Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HanchorBio's current PB Ratio is 47.39, which is 79% above median its own 10-year median of 26.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HanchorBio stock overvalued right now?
HanchorBio (TPE:7827) has a current PB Ratio of 47.39. The current PB Ratio is 47.39, which is 79% above median its 10-year median of 26.46 and 1511.9% above the Biotechnology industry median of 2.94. HanchorBio's overall GF Score™ is 9/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For HanchorBio (TPE:7827), the current PB Ratio is 47.39 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HanchorBio Inc through its subsidiaries, is conducting research and development of new anti-cancer drugs, utilizing an Fc-based biopharmaceutical platform technology to reactivate the immune system in the fight against disease. The core technology of HanchorBio is the FBDB (Fc-Based Designer Biologics) platform, which focuses on the development of next-generation immuno-oncology fusion protein therapeutics. This platform utilizes the antibody Fc region as a backbone, onto which various engineered anti-cancer molecules are constructed through protein engineering. Combined with AI-assisted drug design capabilities, this technology is dedicated to overcoming key challenges in tumor immunotherapy.
9GF Score
Get the complete analysis for TPE:7827
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:7827 has been successfully added to your 
